Okikawa Y - Search Results

1

Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.

Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H, Kubo T, Shimose S, Kimura A. Munemasa S, et al. Among authors: okikawa y. Int J Oncol. 2008 Jul;33(1):129-36. Int J Oncol. 2008. PMID: 18575758

2

Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.

Okikawa Y, Sakai A, Takimoto Y, Noda M, Imagawa J, Katayama Y, Kuroda Y, Okita H, Fujimura K, Kimura A. Okikawa Y, et al. Int J Hematol. 2004 May;79(4):364-8. doi: 10.1532/ijh97.04005. Int J Hematol. 2004. PMID: 15218967

3

Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.

Katayama Y, Sakai A, Okikawa Y, Oue N, Asaoku H, Sasaki A, Imanaka F, Tsujimoto T, Takimoto Y, Masuda R, Nakaju N, Otsuki T, Yasui W, Kimura A. Katayama Y, et al. Among authors: okikawa y. Int J Oncol. 2004 Sep;25(3):579-95. Int J Oncol. 2004. PMID: 15289859

4

The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.

Kuroda Y, Sakai A, Okikawa Y, Munemasa S, Katayama Y, Hyodo H, Imagawa J, Takimoto Y, Okita H, Ohtaki M, Kimura A. Kuroda Y, et al. Among authors: okikawa y. Int J Hematol. 2005 May;81(4):335-41. doi: 10.1532/IJH97.04189. Int J Hematol. 2005. PMID: 15914366 Clinical Trial.

5

Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.

Kuroda Y, Sakai A, Tsuyama N, Katayama Y, Munemasa S, Asaoku H, Okikawa Y, Nakaju N, Mizuno M, Ogawa K, Nishisaka T, Matsui H, Tanaka H, Kimura A. Kuroda Y, et al. Among authors: okikawa y. Int J Oncol. 2008 Dec;33(6):1201-13. Int J Oncol. 2008. PMID: 19020753

6

[Single-agent thalidomide for advanced and refractory multiple myeloma].

Okikawa Y, Takimoto Y, Noda M, Imagawa J, Katayama Y, Sakai A, Okita H, Fujimura K, Kimura A. Okikawa Y, et al. Rinsho Ketsueki. 2003 Jun;44(6):368-74. Rinsho Ketsueki. 2003. PMID: 12884814 Clinical Trial. Japanese.

7

Connective tissue growth factor is an indicator of bone involvement in multiple myeloma, but matrix metalloproteinase-9 is not.

Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H, Kubo T, Miyakawa Y, Serikawa M, Sasaki T, Kimura A. Munemasa S, et al. Among authors: okikawa y. Br J Haematol. 2007 Oct;139(1):41-50. doi: 10.1111/j.1365-2141.2007.06721.x. Br J Haematol. 2007. PMID: 17854305 Free article.

8

[Angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma].

Munemasa S, Sakai A, Sasaki N, Okikawa Y, Mihara K, Kimura A. Munemasa S, et al. Among authors: okikawa y. Rinsho Ketsueki. 2005 Feb;46(2):127-33. Rinsho Ketsueki. 2005. PMID: 16447706 Japanese.

9

Clinical significance of sIL-2R levels in B-cell lymphomas.

Yoshida N, Oda M, Kuroda Y, Katayama Y, Okikawa Y, Masunari T, Fujiwara M, Nishisaka T, Sasaki N, Sadahira Y, Mihara K, Asaoku H, Matsui H, Seto M, Kimura A, Arihiro K, Sakai A. Yoshida N, et al. Among authors: okikawa y. PLoS One. 2013 Nov 13;8(11):e78730. doi: 10.1371/journal.pone.0078730. eCollection 2013. PLoS One. 2013. PMID: 24236041 Free PMC article.

10

Good's syndrome-associated pure red cell aplasia with myelodysplastic syndrome.

Nitta H, Harada Y, Okikawa Y, Fujii M, Arihiro K, Kimura A, Harada H. Nitta H, et al. Among authors: okikawa y. Intern Med. 2011;50(18):2011-4. doi: 10.2169/internalmedicine.50.5709. Epub 2011 Sep 15. Intern Med. 2011. PMID: 21921387 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters